Pasar al contenido principal

DE LA SENCILLEZ EN EL DIAGNOSTICO (NO INVASIVO) Y SEGUIMIENTO DE LA ENFERMEDAD HEPATICA CRONICA AVANZADA A LOS COMPLEJOS MECANISMOS TERAPEUTICOS DE LAS ESTATINAS EN MODELOS ANIMALES

PI18/00947

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON (VHIR)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Proteomic Analysis of Dysfunctional Liver Sinusoidal Endothelial Cells Reveals Substantial Differences in Most Common Experimental Models of Chronic Liver Diseases

  • Gil Soler, Mar
  • Azkargorta, Mikel
  • Fuster Ruiz, Carla
  • Martínez Gómez, María
  • Raurell Saborit, Immaculada
  • Barberá Bellés, Aurora
  • Hide, Diana
  • Martell Pérez-Alcalde, Maria
  • Pericas, Juan M
  • Genesca, Joan
Animal models; Chronic liver disease; Endothelial dysfunction, Models animals; Malaltia hepàtica crònica; Disfunció endotelial, Modelos animales; Enfermedad hepática crónica; Disfunción endotelial, Molecular markers of dedifferentiation of dysfunctional liver sinusoidal endothelial cells (LSEC) have not been fully elucidated. We aimed at deciphering the molecular profile of dysfunctional LSEC in different pathological scenarios. Flow cytometry was used to sort CD11b−/CD32b+ and CD11b−/CD32b− LSEC from three rat models of liver disease (bile duct ligation-BDL; inhaled carbon tetrachloride-CCl4; and high fat glucose/fructose diet-HFGFD). A full proteomic profile was performed applying nano-scale liquid chromatography tandem mass spectrometry (nLC-MS) and analyzed with PEAKS software. The percentage of CD32b− LSEC varied across groups, suggesting different capillarization processes. Both CD32+ and CD32b− LSEC from models are different from control LSEC, but differently expressed proteins in CD32b− LSEC are significantly higher. Heatmaps evidenced specific protein expression patterns for each model. Analysis of biological significance comparing dysfunctional CD32b− LSEC with specialized CD32b+ LSEC from controls showed central similarities represented by 45 common down-regulated proteins involved in the suppression of the endocytic machinery and 63 common up-regulated proteins associated with the actin-dependent cytoskeleton reorganization. In summary; substantial differences but also similarities in dysfunctional LSEC from the three most common models of liver disease were found, supporting the idea that LSEC may harbor different protein expression profiles according to the etiology or disease stage., This work was supported by grants PI18/00947 and AC18/00033 (ENM3 2018) and PI21/00691 from Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union (ERDF/ESF, “Investing in your future”). J.G. is the recipient of a clinical intensification award and D.H. of a Sara Borrell grant, both from ISCIII. M.G. and A.B. have predoctoral fellowships from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) and ISCIII respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII. The APC was funded by ISCIII.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Review article: The need for more efficient and patient-oriented drug development pathways in NASH—setting the scene for platform trials

  • Di Prospero, Nicholas A.
  • Anstee, Quentin M.
  • Mesenbrinck, Peter
  • Kjær, Mette S
  • Rivera-Esteban, Jesús
  • Sena, Elena
  • Genesca, Joan
  • Pericas, Juan M
  • Manzano-Nunez, Ramiro
Drug development; Non-alcoholic steatohepatitis; Study designs, Desenvolupament de fàrmacs; Esteatohepatitis no alcohòlica; Dissenys d'estudi, Desarrollo de fármacos; Esteatohepatitis no alcohólica; Diseños de estudio, Background and Aims Non-alcoholic steatohepatitis (NASH) constitutes a significant unmet medical need with a burgeoning field of clinical research and drug development. Platform trials (PT) might help accelerate drug development while lowering overall costs and creating a more patient-centric environment. This review provides a comprehensive and nuanced assessment of the NASH clinical development landscape. Methods Narrative review and expert opinion with insight gained during the EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project. Results Although NASH represents an opportunity to use adaptive trial designs, including master protocols for PT, there are barriers that might be encountered owing to distinct and sometimes opposing priorities held by these stakeholders and potential ways to overcome them. The following aspects are critical for the feasibility of a future PT in NASH: readiness of the drug pipeline, mainly from large drug companies, while there is not yet an FDA/EMA-approved treatment; the most suitable design (trial Phase and type of population, e.g., Phase 2b for non-cirrhotic NASH patients); the operational requirements such as the scope of the clinical network, the use of concurrent versus non-concurrent control arms, or the re-allocation of participants upon trial adaptations; the methodological appraisal (i.e. Bayesian vs. frequentist approach); patients' needs and patient-centred outcomes; main regulatory considerations and the funding and sustainability scenarios. Conclusions PT represent a promising avenue in NASH but there are a number of conundrums that need addressing. It is likely that before a global NASH PT becomes a reality, ‘proof-of-platform’ at a smaller scale needs to be provided., JMP reports having received consulting fees from Boehringer-Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. NAdP works for Janssen. QMA is Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multistakeholder consortium includes industry partners. He reports research Grant Funding: Allergan/Tobira, AstraZeneca, Boehringer-Ingelheim, Glaxo SmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd. Consultancy: 89Bio, Abbvie/Allergan, Akero, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer-Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics. Speaker: Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape. Royalties: Elsevier Ltd. PM works for Novartis. MSK is an employee of and a shareholder in Novo Nordisk A/S. JG has received consulting fees from Boehringer-Ingelheim, speaking fees from Echosens and travel expenses from Gilead and Abbie. Funds from ISCIII PI18/00947 and PI21/00691. JRE has received speaking fees from Gilead. FT lab’ work has been supported by the German Research Foundation (DFG, CRC/TR 362) and research grants from Gilead, Allergan, Bristol-Myers Squibb and Inventiva. VR consults for and Intercept, Novo Nordisk, Galmed, Poxel, NGM, Madrigal, Enyo, Sagimet, 89 Bio, Prosciento, Terns, and Theratechnologies, and received grants from Intercept and Gilead.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis

  • Ventura Cots, Meritxell
  • Simon-Talero Horga, Macarena
  • Poca Pastor, Ma Antonia
  • Ariza, Xavier
  • Masnou, Helena
  • Sanchez, Jordi
  • Torrens Buscató, Maria Margarita
  • Genescà Ferrer, Joan
Albúmina; Assaig clínic; Metanàlisi, Albumin; Clinical trial; Meta-analysis, Albúmina; Ensayo clínico; Metaanálisis, No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. Methods: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient’s data for survival including two clinical trials (BETA and ALFAE) was performed. Results: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21–0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). Conclusions: Repeated doses of albumin might be beneficial for patient’s survival as an add-on therapy after an HE episode, but an adequately powered trial is needed., This work was supported by grants ICI14/00352 and PI/18/00947 from Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (ERDF/ESF, “Investing in your future”—Una manera de hacer Europa). MVC and MST are both recipients of Juan Rodes grants from ISCIII. JG is a recipient of a research intensification grant from the ISCIII. CIBERehd is supported by ISCIII. ACS is a recipient of the Rio Hortega grant from ISCIII. The work was independent of all funding.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH

  • Bravo Garmendia, Miren
  • Raurell Saborit, Immaculada
  • Barbera Belles, Aurora
  • Hide Alferez, Diana
  • Estrella Gonzalez, Federico
  • Salcedo Allende, Maria Teresa
  • Genescà Ferrer, Joan
  • Gil Soler, Mar
  • Martell Pérez-Alcalde, Maria
  • Augustin Recio, Salvador
Ambrisentan; Endotelina-1; Cèl·lules estelades hepàtiques, Ambrisentan; Endotelina-1; Células estrelladas hepáticas, Ambrisentan; Endothelin-1; Hepatic stellate cells, In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisentan is a selective endothelin-receptor-A antagonist. We aimed to analyse the combined effects of atorvastatin and ambrisentan on liver histopathology and hemodynamics, together with assessing the underlying mechanism in a rat NASH model. Diet-induced NASH rats were treated with atorvastatin (10 mg/kg/day), ambrisentan (30 mg/kg/day or 2 mg/kg/day) or a combination of both for 2 weeks. Hemodynamic parameters were registered and liver histology and serum biochemical determinations analysed. Expression of proteins were studied by immunoblotting. Conditioned media experiments were performed with LSEC. HSCs were characterized by RT-PCR, and a collagen lattice contraction assay was performed. Atorvastatin and ambrisentan act synergistically in combination to completely normalize liver hemodynamics and reverse histological NASH by 75%. Atorvastatin reversed the sinusoidal contractile phenotype, thus improving endothelial function, whereas ambrisentan prevented the contractile response in HSCs by blocking ET-1 response. Additionally, ambrisentan also increased eNOS (also known as Nos3) phosphorylation levels in LSEC, via facilitating the stimulation of endothelin-receptor-B in these cells. Furthermore, the serum alanine aminotransferase of the combined treatment group decreased to normal levels, and this group exhibited a restoration of the HSC quiescent phenotype. The combination of atorvastatin and ambrisentan remarkably improves liver histology and PH in a diet-induced NASH model. By recovering LSEC function, together with inhibiting the activation and contraction of HSC, this combined treatment may be an effective treatment for NASH patients., This work was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (European Regional Development Fund/European Social Fund, ‘Investing in your future’) [PI17/00310 to S.A., PI17/00754 to M.M., and PI18/00947 and AC18/00033 (ENM3 2018) to J.G.]. J.G. is a recipient of a clinical intensification award and D.H. is a recipient of a Sara Borrell grant (both from ISCIII). M.G. and A.B. have predoctoral fellowships from the Agència de Gestió d'Ajuts Universitaris i de Recerca and ISCIII, respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH

  • Bravo, Miren|||0000-0001-5889-9125
  • Raurell, Imma|||0000-0003-4477-7367
  • Hide, Diana
  • Fernández-Iglesias, Anabel|||0000-0003-2364-6675
  • Gil, Mar
  • Barberá Bellés, Aurora|||0000-0002-6201-2643
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Martell, María|||0000-0002-0935-0029
Non-alcoholic steatohepatitis (NASH) is a common chronic liver disorder in developed countries, with the associated clinical complications driven by portal hypertension (PH). PH may precede fibrosis development, probably due to endothelial dysfunction at early stages of the disease. Our aim was to characterize liver sinusoidal endothelial cell (LSEC) dedifferentiation/capillarization and its contribution to PH in NASH, together with assessing statins capability to revert endothelial function improving early NASH stages. Sprague-Dawley rats were fed with high fat glucose-fructose diet (HFGFD), or control diet (CD) for 8 weeks and then treated with simvastatin (sim) (10 mg·kg·day), atorvastatin (ato) (10 mg·kg·day) or vehicle during 2 weeks. Biochemical, histological and hemodynamic determinations were carried out. Sinusoidal endothelial dysfunction was assessed in individualized sorted LSEC and hepatic stellate cells (HSC) from animal groups and in whole liver samples. HFGFD rats showed full NASH features without fibrosis but with significantly increased portal pressure compared with CD rats (10.47 ± 0.37 mmHg vs 8.30 ± 0.22 mmHg; p < 0.001). Moreover, HFGFD rats showed a higher percentage of capillarized (CD32b/CD11b) LSEC (8% vs 1%, p = 0.005) showing a contractile phenotype associated to HSC activation. Statin treatments caused a significant portal pressure reduction (sim: 9.29 ± 0.25 mmHg, p < 0.01; ato: 8.85 ± 0.30 mmHg, p < 0.001), NASH histology reversion, along with significant recovery of LSEC differentiation and a regression of HSC activation to a more quiescent phenotype. In an early NASH model without fibrosis with PH, LSEC transition to capillarization and HSC activation are reverted by statin treatment inducing portal pressure decrease and NASH features improvement.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Spontaneous portosystemic shunts in liver cirrhosis, new approaches to an old problem

  • Vidal-González, Judit
  • Quiroga, Sergio|||0000-0001-8671-7616
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Portal hypertension is the main consequence of liver cirrhosis, leading to severe complications such as variceal hemorrhage, ascites or hepatic encephalopathy. As an attempt to decompress the portal venous system, portal flow is derived into the systemic venous system through spontaneous portosystemic shunts (SPSSs), bypassing the liver. In this review, we aim to provide an overview of the published reports in relation to the prevalence and physiopathology behind the appearance of SPSS in liver cirrhosis, as well as the complications derived from its formation and its management. The role of SPSS embolization is specifically discussed, as SPSSs have been assessed as a therapeutic target, mainly for patients with recurrent/persistent hepatic encephalopathy and preserved liver function. Furthermore, different aspects of the role of SPSS in liver transplantation, as well as in candidates for transjugular intrahepatic portosystemic shunt are reviewed. In these settings, SPSS occlusion has been proposed to minimize possible deleterious effects, but results are so far inconclusive.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH

  • Bravo, Miren|||0000-0001-5889-9125
  • Raurell, Imma|||0000-0003-4477-7367
  • Barberá Bellés, Aurora|||0000-0002-6201-2643
  • Hide, Diana
  • Gil, Mar
  • Estrella, Federico
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Martell, María|||0000-0002-0935-0029
In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisentan is a selective endothelin-receptor-A antagonist. We aimed to analyse the combined effects of atorvastatin and ambrisentan on liver histopathology and hemodynamics, together with assessing the underlying mechanism in a rat NASH model. Diet-induced NASH rats were treated with atorvastatin (10 mg/kg/day), ambrisentan (30 mg/kg/day or 2 mg/kg/day) or a combination of both for 2 weeks. Hemodynamic parameters were registered and liver histology and serum biochemical determinations analysed. Expression of proteins were studied by immunoblotting. Conditioned media experiments were performed with LSEC. HSCs were characterized by RT-PCR, and a collagen lattice contraction assay was performed. Atorvastatin and ambrisentan act synergistically in combination to completely normalize liver hemodynamics and reverse histological NASH by 75%. Atorvastatin reversed the sinusoidal contractile phenotype, thus improving endothelial function, whereas ambrisentan prevented the contractile response in HSCs by blocking ET-1 response. Additionally, ambrisentan also increased eNOS (also known as Nos3) phosphorylation levels in LSEC, via facilitating the stimulation of endothelin-receptor-B in these cells. Furthermore, the serum alanine aminotransferase of the combined treatment group decreased to normal levels, and this group exhibited a restoration of the HSC quiescent phenotype. The combination of atorvastatin and ambrisentan remarkably improves liver histology and PH in a diet-induced NASH model. By recovering LSEC function, together with inhibiting the activation and contraction of HSC, this combined treatment may be an effective treatment for NASH patients. Summary: Combining atorvastatin with ambrisentan is safe and effective in reducing intrahepatic resistance and portal hypertension in an experimental model of NASH. This liver histology amelioration highlights a promising therapeutic strategy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Campos Varela, Isabel|||0000-0001-6597-3151
  • Villagrasa, Ares|||0000-0003-0928-0427
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Aguilera-Castro, Lara
  • Álvarez-López, Patricia|||0000-0003-4227-1987
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan|||0000-0002-1966-1947
  • Barber Caselles, Claudia|||0000-0003-4711-2731
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Biagetti, Betina|||0000-0002-8837-4343
  • Camps-Relats, Laura
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Cocera, Raul
  • Dopazo, Cristina|||0000-0001-6274-5911
  • Fernandez, Andrea
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Jiménez, María M.
  • Jofra Castells, Mariona|||0000-0002-3034-4985
  • Gil, Clara
  • Gómez Gavara, Concepción|||0000-0001-8312-3273
  • Guanozzi, Danila
  • Guevara, Jorge A.
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Malagelada Prats, Carolina|||0000-0001-7097-1492
  • Martínez-Campreciós, Joan|||0000-0002-8899-8447
  • Mayorga, Luis
  • Miret Alomar, Enric|||0000-0002-6656-5050
  • Pando, Elizabeth|||0000-0001-6898-5502
  • Pérez-Lopez, Ana
  • Pigrau Pastor, Marc|||0000-0001-6801-3017
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Romero, Alba
  • Tasayco, Staphanie|||0000-0001-7867-349X
  • Vidal-Gonzalez, Judit
  • Vidal Piñeiro, Laura|||0000-0003-3757-3323
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Augustin Recio, Salvador|||0000-0002-3515-9033
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effects of albumin on survival after a hepatic encephalopathy episode, Randomized double-blind trial and meta-analysis

  • Ventura-Cots, Meritxell|||0000-0001-9513-2855
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Poca Sans, Maria|||0000-0002-0235-1395
  • Ariza, Xavier
  • Masnou, Helena|||0000-0003-0632-1393
  • Sánchez Delgado, Jordi|||0000-0002-5217-6492
  • Llop, Elba
  • Cañete Hidalgo, Nuria|||0000-0001-9501-7590
  • Martín-Llahí, Marta
  • Amador, Alberto
  • Martínez, Javier
  • Clemente-Sanchez, Ana
  • Puente, Angela
  • Torrens, Maria|||0000-0003-3479-0066
  • Alvarado-Tapias, Edilmar|||0000-0003-2036-6133
  • Napoleone, Laura
  • Miquel Planas, Mireia|||0000-0003-4566-4962
  • Ardèvol Ribalta, Alba
  • Casas, Meritxell|||0000-0001-7227-7277
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • Solé Martí, Cristina|||0000-0002-6104-8345
  • Soriano, German|||0000-0002-9267-6811
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. Methods: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient's data for survival including two clinical trials (BETA and ALFAE) was performed. Results: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21-0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). Conclusions: Repeated doses of albumin might be beneficial for patient's survival as an add-on therapy after an HE episode, but an adequately powered trial is needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD, A proof of concept case report

Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH

  • Bravo Garmendia, Miren
  • Raurell Saborit, Immaculada
  • Barbera Belles, Aurora
  • Hide Alferez, Diana
  • Estrella Gonzalez, Federico
  • Salcedo Allende, Maria Teresa
  • Genescà Ferrer, Joan
  • Gil Soler, Mar
  • Martell Pérez-Alcalde, Maria
  • Augustin Recio, Salvador
Ambrisentan; Endotelina-1; Cèl·lules estelades hepàtiques, Ambrisentan; Endotelina-1; Células estrelladas hepáticas, Ambrisentan; Endothelin-1; Hepatic stellate cells, In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisentan is a selective endothelin-receptor-A antagonist. We aimed to analyse the combined effects of atorvastatin and ambrisentan on liver histopathology and hemodynamics, together with assessing the underlying mechanism in a rat NASH model. Diet-induced NASH rats were treated with atorvastatin (10 mg/kg/day), ambrisentan (30 mg/kg/day or 2 mg/kg/day) or a combination of both for 2 weeks. Hemodynamic parameters were registered and liver histology and serum biochemical determinations analysed. Expression of proteins were studied by immunoblotting. Conditioned media experiments were performed with LSEC. HSCs were characterized by RT-PCR, and a collagen lattice contraction assay was performed. Atorvastatin and ambrisentan act synergistically in combination to completely normalize liver hemodynamics and reverse histological NASH by 75%. Atorvastatin reversed the sinusoidal contractile phenotype, thus improving endothelial function, whereas ambrisentan prevented the contractile response in HSCs by blocking ET-1 response. Additionally, ambrisentan also increased eNOS (also known as Nos3) phosphorylation levels in LSEC, via facilitating the stimulation of endothelin-receptor-B in these cells. Furthermore, the serum alanine aminotransferase of the combined treatment group decreased to normal levels, and this group exhibited a restoration of the HSC quiescent phenotype. The combination of atorvastatin and ambrisentan remarkably improves liver histology and PH in a diet-induced NASH model. By recovering LSEC function, together with inhibiting the activation and contraction of HSC, this combined treatment may be an effective treatment for NASH patients., This work was supported by the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (European Regional Development Fund/European Social Fund, ‘Investing in your future’) [PI17/00310 to S.A., PI17/00754 to M.M., and PI18/00947 and AC18/00033 (ENM3 2018) to J.G.]. J.G. is a recipient of a clinical intensification award and D.H. is a recipient of a Sara Borrell grant (both from ISCIII). M.G. and A.B. have predoctoral fellowships from the Agència de Gestió d'Ajuts Universitaris i de Recerca and ISCIII, respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis

  • Ventura Cots, Meritxell
  • Simon-Talero Horga, Macarena
  • Poca Pastor, Ma Antonia
  • Ariza, Xavier
  • Masnou, Helena
  • Sanchez, Jordi
  • Torrens Buscató, Maria Margarita
  • Genescà Ferrer, Joan
Albúmina; Assaig clínic; Metanàlisi, Albumin; Clinical trial; Meta-analysis, Albúmina; Ensayo clínico; Metaanálisis, No therapies have been proven to increase survival after a hepatic encephalopathy (HE) episode. We hypothesize that two doses of albumin could improve 90-day survival rates after a HE episode. Methods: (1) A randomized double-blind, placebo-controlled trial (BETA) was conducted in 12 hospitals. The effect of albumin (1.5 g/kg at baseline and 1 g/kg on day 3) on 90-day survival rates after a HE episode grade II or higher was evaluated. (2) A meta-analysis of individual patient’s data for survival including two clinical trials (BETA and ALFAE) was performed. Results: In total, 82 patients were included. Albumin failed to increase the 90-day transplant-free survival (91.9% vs. 80.5%, p = 0.3). A competing risk analysis was performed, observing a 90-day cumulative incidence of death of 9% in the albumin group vs. 20% in the placebo (p = 0.1). The meta-analysis showed a benefit in the albumin group, with a lower rate of clinical events (death or liver transplant) than patients in the placebo (HR, 0.44; 95% CI, 0.21–0.82), when analyzed by a competing risk analysis (90-days mortality rate of 11% in the albumin group vs. 30% in the placebo, p = 0.02). Conclusions: Repeated doses of albumin might be beneficial for patient’s survival as an add-on therapy after an HE episode, but an adequately powered trial is needed., This work was supported by grants ICI14/00352 and PI/18/00947 from Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (ERDF/ESF, “Investing in your future”—Una manera de hacer Europa). MVC and MST are both recipients of Juan Rodes grants from ISCIII. JG is a recipient of a research intensification grant from the ISCIII. CIBERehd is supported by ISCIII. ACS is a recipient of the Rio Hortega grant from ISCIII. The work was independent of all funding.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

  • Miret Campos Varela, Isabel
  • Villagrasa Vilella, Ares Aurora
  • Simon-Talero Horga, Macarena
  • Riveiro Barciela, Maria del Mar
  • Ventura Cots, Meritxell
  • Álvarez López, Patricia
  • Nordahl, Emilie Anderssen
  • Anton, Adrian
  • Bañares, Juan
  • Barreira Diaz, Ana
  • Biagetti Biagetti, Betina
  • Camps-Relats, Laura
  • Cocera Rodriguez, Raul
  • Dopazo Taboada, Cristina
  • Fernandez Pujol, Andrea
  • Jimenez Hernandez, Cesar
  • Matarín Jiménez, Maria del Mar
  • Jofra, Mariona
  • Gil, Clara
  • Gomez Gavara, Concepción
  • Guevara Cubas, Jorge Alonso
  • Lobo Alvarez, Beatriz
  • Malagelada Prats, Carolina
  • Martínez Campreciós, Joan
  • Pando Rau, Elizabeth
  • Perez-Lopez, Ana
  • Prio, Alba
  • Rivera Esteban, Jesus Manuel
  • Romero, Alba
  • Tasayco Huaman, Stephanie Solange
  • Vidal Gonzalez, Judit
  • Vidal Piñeiro, Laura
  • Minguez Rosique, Beatriz
  • Genescà Ferrer, Joan
  • Ciudin Mihai, Andreea
  • Barber Caselles, Claudia
  • Augustin Recio, Salvador
  • Aguilera Castro, Lara
  • Guagnozzi, Danila
  • Miret Alomar, Enric
  • Pigrau Pastor, Marc
  • Mayorga Ayala, Luis Fernando
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Paràmetre d'atenuació controlat; Lesió hepàtica, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Parámetro de atenuación controlado; Daño hepático, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Controlled attenuation parameter; Liver injury, Liver injury has been widely described in patients with Coronavirus disease 2019 (COVID-19). We aimed to study the effect of liver biochemistry alterations, previous liver disease, and the value of liver elastography on hard clinical outcomes in COVID-19 patients. We conducted a single-center prospective observational study in 370 consecutive patients admitted for polymerase chain reaction (PCR)-confirmed COVID-19 pneumonia. Clinical and laboratory data were collected at baseline and liver parameters and clinical events recorded during follow-up. Transient elastography [with Controlled Attenuation Parameter (CAP) measurements] was performed at admission in 98 patients. All patients were followed up until day 28 or death. The two main outcomes of the study were 28-day mortality and the occurrence of the composite endpoint intensive care unit (ICU) admission and/or death. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were elevated at admission in 130 patients (35%) and 167 (45%) patients, respectively. Overall, 14.6% of patients presented the composite endpoint ICU and/or death. Neither ALT elevations, prior liver disease, liver stiffness nor liver steatosis (assessed with CAP) had any effect on outcomes. However, patients with abnormal baseline AST had a higher occurrence of the composite ICU/death (21% versus 9.5%, p = 0.002). Patients ⩾65 years and with an AST level > 50 U/ml at admission had a significantly higher risk of ICU and/or death than those with AST ⩽ 50 U/ml (50% versus 13.3%, p < 0.001). In conclusion, mild liver damage is prevalent in COVID-19 patients, but neither ALT elevation nor liver steatosis influenced hard clinical outcomes. Elevated baseline AST is a strong predictor of hard outcomes, especially in patients ⩾65 years., The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JG is a recipient of a Research Intensification grant from the Instituto de Salud Carlos III, Spain. MST and MVC are recipients of a Juan Rodés grant from the Instituto de Salud Carlos III. The work was partially funded by grants PI17/00310, PI18/00947, PI18/00961, and PI19/00330 from Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future” – Una manera de hacer Europa). CIBERehd is supported by Instituto de Salud Carlos III. The work was independent of all funding.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Proteomic Analysis of Dysfunctional Liver Sinusoidal Endothelial Cells Reveals Substantial Differences in Most Common Experimental Models of Chronic Liver Diseases

  • Gil Soler, Mar
  • Azkargorta, Mikel
  • Fuster Ruiz, Carla
  • Martínez Gómez, María
  • Raurell Saborit, Immaculada
  • Barberá Bellés, Aurora
  • Hide, Diana
  • Martell Pérez-Alcalde, Maria
  • Pericas, Juan M
  • Genesca, Joan
Animal models; Chronic liver disease; Endothelial dysfunction, Models animals; Malaltia hepàtica crònica; Disfunció endotelial, Modelos animales; Enfermedad hepática crónica; Disfunción endotelial, Molecular markers of dedifferentiation of dysfunctional liver sinusoidal endothelial cells (LSEC) have not been fully elucidated. We aimed at deciphering the molecular profile of dysfunctional LSEC in different pathological scenarios. Flow cytometry was used to sort CD11b−/CD32b+ and CD11b−/CD32b− LSEC from three rat models of liver disease (bile duct ligation-BDL; inhaled carbon tetrachloride-CCl4; and high fat glucose/fructose diet-HFGFD). A full proteomic profile was performed applying nano-scale liquid chromatography tandem mass spectrometry (nLC-MS) and analyzed with PEAKS software. The percentage of CD32b− LSEC varied across groups, suggesting different capillarization processes. Both CD32+ and CD32b− LSEC from models are different from control LSEC, but differently expressed proteins in CD32b− LSEC are significantly higher. Heatmaps evidenced specific protein expression patterns for each model. Analysis of biological significance comparing dysfunctional CD32b− LSEC with specialized CD32b+ LSEC from controls showed central similarities represented by 45 common down-regulated proteins involved in the suppression of the endocytic machinery and 63 common up-regulated proteins associated with the actin-dependent cytoskeleton reorganization. In summary; substantial differences but also similarities in dysfunctional LSEC from the three most common models of liver disease were found, supporting the idea that LSEC may harbor different protein expression profiles according to the etiology or disease stage., This work was supported by grants PI18/00947 and AC18/00033 (ENM3 2018) and PI21/00691 from Instituto de Salud Carlos III (ISCIII) and cofounded by the European Union (ERDF/ESF, “Investing in your future”). J.G. is the recipient of a clinical intensification award and D.H. of a Sara Borrell grant, both from ISCIII. M.G. and A.B. have predoctoral fellowships from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) and ISCIII respectively. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) is supported by ISCIII. The APC was funded by ISCIII.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Review article: The need for more efficient and patient-oriented drug development pathways in NASH—setting the scene for platform trials

  • Di Prospero, Nicholas A.
  • Anstee, Quentin M.
  • Mesenbrinck, Peter
  • Kjær, Mette S
  • Rivera-Esteban, Jesús
  • Sena, Elena
  • Genesca, Joan
  • Pericas, Juan M
  • Manzano-Nunez, Ramiro
Drug development; Non-alcoholic steatohepatitis; Study designs, Desenvolupament de fàrmacs; Esteatohepatitis no alcohòlica; Dissenys d'estudi, Desarrollo de fármacos; Esteatohepatitis no alcohólica; Diseños de estudio, Background and Aims Non-alcoholic steatohepatitis (NASH) constitutes a significant unmet medical need with a burgeoning field of clinical research and drug development. Platform trials (PT) might help accelerate drug development while lowering overall costs and creating a more patient-centric environment. This review provides a comprehensive and nuanced assessment of the NASH clinical development landscape. Methods Narrative review and expert opinion with insight gained during the EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) project. Results Although NASH represents an opportunity to use adaptive trial designs, including master protocols for PT, there are barriers that might be encountered owing to distinct and sometimes opposing priorities held by these stakeholders and potential ways to overcome them. The following aspects are critical for the feasibility of a future PT in NASH: readiness of the drug pipeline, mainly from large drug companies, while there is not yet an FDA/EMA-approved treatment; the most suitable design (trial Phase and type of population, e.g., Phase 2b for non-cirrhotic NASH patients); the operational requirements such as the scope of the clinical network, the use of concurrent versus non-concurrent control arms, or the re-allocation of participants upon trial adaptations; the methodological appraisal (i.e. Bayesian vs. frequentist approach); patients' needs and patient-centred outcomes; main regulatory considerations and the funding and sustainability scenarios. Conclusions PT represent a promising avenue in NASH but there are a number of conundrums that need addressing. It is likely that before a global NASH PT becomes a reality, ‘proof-of-platform’ at a smaller scale needs to be provided., JMP reports having received consulting fees from Boehringer-Ingelheim, MSD and Novo Nordisk. He has received speaking fees from Gilead, Intercept, and Novo Nordisk, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Madrigal, Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD. Funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. NAdP works for Janssen. QMA is Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA. This multistakeholder consortium includes industry partners. He reports research Grant Funding: Allergan/Tobira, AstraZeneca, Boehringer-Ingelheim, Glaxo SmithKline, Glympse Bio, Intercept, Novartis Pharma AG, Pfizer Ltd. Consultancy: 89Bio, Abbvie/Allergan, Akero, Altimentiv, Altimmune, AstraZeneca, Axcella, Blade, BMS, BNN Cardio, Boehringer-Ingelheim, Cirius, CymaBay, EcoR1, E3Bio, Eli Lilly & Company Ltd., Galmed, Genentech, Genfit SA, Gilead, Grunthal, HistoIndex, Indalo, Intercept Pharma Europe Ltd., Inventiva, IQVIA, Janssen, Johnson & Johnson, Madrigal, MedImmune, Medpace, Merck, Metacrine, NGMBio, North Sea Therapeutics, Novartis, Novo Nordisk A/S, PathAI, Pfizer Ltd., Poxel, ProSciento, Raptor Pharma, Roche, Servier, Shionogi, Terns, The Medicines Company, Viking Therapeutics. Speaker: Abbott Laboratories, Allergan/Tobira, BMS, Clinical Care Options, Falk, Fishawack, Genfit SA, Gilead, Integritas Communications, Kenes, Medscape. Royalties: Elsevier Ltd. PM works for Novartis. MSK is an employee of and a shareholder in Novo Nordisk A/S. JG has received consulting fees from Boehringer-Ingelheim, speaking fees from Echosens and travel expenses from Gilead and Abbie. Funds from ISCIII PI18/00947 and PI21/00691. JRE has received speaking fees from Gilead. FT lab’ work has been supported by the German Research Foundation (DFG, CRC/TR 362) and research grants from Gilead, Allergan, Bristol-Myers Squibb and Inventiva. VR consults for and Intercept, Novo Nordisk, Galmed, Poxel, NGM, Madrigal, Enyo, Sagimet, 89 Bio, Prosciento, Terns, and Theratechnologies, and received grants from Intercept and Gilead.